Search
for
Sort by
Research 61–90 of 540
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Cytokine Targeted Therapeutics for Alopecia Areata: Lessons from Atopic Dermatitis and Other Inflammatory Skin Diseases
- Lack of efficacy of apremilast in 9 patients with severe alopecia areata
- Persistent Sexual Dysfunction with Finasteride 1 mg Taken for Hair Loss
- Monovalent antibody-conjugated lipid-polymer nanohybrids for active targeting to desmoglein 3 of keratinocytes to attenuate psoriasiform inflammation
- Insights learned from L457(3.43)R, an activating mutant of the human lutropin receptor
- 5-Alpha-Reductase Inhibitors and Combination Therapy
- Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
- Effect of a transcriptional inactive or absent vitamin D receptor on beta-cell function and glucose homeostasis in mice
- Role of caffeine in the management of androgenetic alopecia
- Apremilast is efficacious in refractory alopecia areata
- Drug repurposing of cyclin-dependent kinase inhibitors for neutrophilic acute respiratory distress syndrome and psoriasis
- The ‘bald’ phenotype (androgenetic alopecia) is caused by the high glycaemic, high cholesterol and low mineral ‘western diet’
- Therapeutic use of caffeine in dermatology: A literature review
- Alopecia areata: from pathophysiology to therapeutic innovation
- Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
- Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis
- Approaching Erectile Dysfunction in Dermatology Patients
- Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport
- The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Alopesi Tedavisinde Kullanılan İlaç Tedavileri ve Yeni Yaklaşımlar
- Medical management of benign prostatic hyperplasia
- Platelet-Rich Plasma for Urologic Conditions: An Early Call for Composition Reporting
- The pharmacological treatment of alopecia areata
- 1113 Targeting anti-inflammatory immunonanocarriers to human and murine neutrophils via Ly6 antigen for psoriasiform dermatitis alleviation
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- 22-Year-Old Male with Several Discrete Patches of Hair Loss